- Companies
- BlinkRx
BlinkRx Valuation, Funding & Investors
BlinkRx is valued at $2B as of November 2024.
Last BlinkRx valuation
$2B
Series D · Nov 2024
Last BlinkRx funding round
$140M
Series D · Nov 2024
Cumulative funding BlinkRx raised
$315M
across 4 funding rounds
Key investors in BlinkRx
8VC
BoxGroup
LeFrak
SuRo Capital
Burch Creative Capital
The K Fund
About BlinkRx
BlinkRx, operating under the Blink Health brand, is a New York-based prescription access platform founded in 2014 by brothers Geoffrey and Matthew Chaiken. It lets patients purchase prescription medications online at reduced prices and have them delivered to their homes or a local pharmacy, negotiating directly with drug manufacturers to bring down costs. The company has said it aims to bring pricing transparency and affordability to prescription drugs, and its infrastructure has also supported TrumpRx, a government-run website for direct-to-consumer drug purchasing.
Founded
2014
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Commission
Valuation
$2B (Nov 2024)
BlinkRx Valuation
BlinkRx is currently valued at $2B, based on its Series D in November 2024.
The $140M round was led by 1789 Capital.
BlinkRx's valuation has grown 2.4x from $829M at its Series A in October 2020 to $2B in November 2024, across 2 priced rounds.
BlinkRx valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Nov 2024 | Series D | $2B |
| Oct 2020 | Series A | $829M |
BlinkRx Funding History
BlinkRx has raised a total of $315M across 4 funding rounds.
BlinkRx's first fundraising round was a $75M Series A in April 2016. The most recent completed round was a $140M Series D in November 2024.
BlinkRx funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Nov 2024 | Series D | 1789 Capital (lead) | $140M | $2B | BlinkRx is a prescription access platform founded in 2014 by brothers Geoffrey and Matthew Chaiken that aims to make prescription medications more affordable and accessible to patients. The company operates a technology platform allowing users to purchase prescriptions online at lower prices and have them delivered to their homes or local pharmacies, negotiating with drug manufacturers and using technology to streamline the prescription process. In November 2024, BlinkRx completed a Series D funding round that raised $140 million, with 1789 Capital serving as the lead investor. The round valued the company at $1.62 billion post-money valuation, with additional investors including 8vc, Cercano Management, and Fidelity Investments. Following the funding round, Donald Trump Jr., a partner at 1789 Capital, joined BlinkRx's Board of Directors. The company's platform is known for bringing transparency, accessibility, and affordability to patients seeking prescription medications. As of September 2025, BlinkRx was reported to be facilitating TrumpRx, a government-run website where consumers could purchase prescription drugs directly from manufacturers like Pfizer, following a May 2025 executive order directing pharmaceutical manufacturers to offer online purchasing options without requiring insurance. |
| Oct 2020 | Series A | SuRo Capital (lead); The K Fund; Sweetwater Capital Partners | $10M | $829M | Blink Health is a healthcare technology company founded in 2014 by brothers Geoffrey and Matthew Chaiken and headquartered in New York, NY. The company operates a platform that makes prescription medications more affordable and accessible by offering transparent pricing, online purchases, and delivery to homes or local pharmacies. It negotiates directly with drug manufacturers and uses technology to streamline the prescription process for lower costs than traditional pharmacies. On October 27, 2020, Blink Health raised $205.25 million in its Series C round led by SuRo Capital, with participation from investors including Sweetwater Private Equity and The K Fund. The post-money valuation for this round reached $829.2 million, with a price per share of $38.18. Total funding raised by the company across rounds amounted to $583.89 million as of the latest reported data. Blink Health continued growth with subsequent rounds, including a Series D in November 2024 at a $1.62 billion valuation. Major investors in the company include 8vc, BoxGroup, Burch Creative Capital, Hunt Technology Ventures, Lefrak, Medimpact Healthcare Systems, Melo7 Tech Partners, Teamworthy Ventures, and The Cambria Group. |
| Apr 2017 | Series B | 8VC (lead); BoxGroup; Burch Creative Capital | $90M | - | Blink Health, operating as BlinkRx in some contexts, is a New York-based digital health startup that provides a platform for discounted prescription medications, enabling patients to access lower prices on generics and branded drugs through transparency and direct negotiations with drugmakers and pharmacies. The company announced a $90 million Series B funding round on April 12, 2017, led by 8VC, with participation from investors including BoxGroup and Burch Creative Capital, bringing total financing to $165 million following a prior $75 million Series A also led by 8VC. Funds were allocated to drive technological innovations, hire engineers, expand marketing, and accelerate the mission of affordable, transparent drug pricing amid rising out-of-pocket costs and uninsured populations. Blink Health had demonstrated strong early traction with approximately 1 million monthly users by early 2017, described as growing exponentially, and partnerships like one with Eli Lilly and Express Scripts in December 2016 to offer up to 40% discounts on insulins, enabling rebate pass-throughs previously unavailable for branded medications. The platform earns a fixed cut per transaction rather than a percentage of list prices, differentiating it from traditional pharmacy benefit managers, and aimed to onboard all drug manufacturers due to its quick setup without contract changes. However, it faced challenges such as Walgreens exiting the network in March 2017 after failed renewal talks. The round underscored investor confidence in Blink Health's technology to disrupt the opaque prescription drug supply chain, with 8VC founder Joe Lonsdale highlighting its potential to lower prices akin to other commerce sectors. CEO Geoffrey Chaiken and COO Matthew Chaiken emphasized its role for consumers facing high deductibles and uninsured status. Subsequent funding continued, including later rounds like a $140 million Series D in 2024 led by 1789 Capital, with total raised exceeding $500 million across multiple stages. |
| Apr 2016 | Series A | 8VC (lead); LeFrak | $75M | - | BlinkRx appears to refer to Blink Health, a New York-based digital health startup founded around 2014-2016 that operates as a prescription discount platform, often dubbed the 'Expedia for prescription drugs,' offering transparent pricing and discounts on medications directly from drugmakers to consumers without involving health insurance. The company negotiates prices for generics and branded drugs, passing savings to users via a mobile app, and earns a fixed cut per transaction rather than a percentage of list prices. In late 2016 (approximate date Dec 4), Blink Health raised a $75 million Series A round led by 8VC, with participation from investors including LeFrak, as confirmed across multiple reports. This was followed by a $90 million Series B in April 2017 also led by 8VC, bringing total funding to $165 million at that point, used for engineering hires, marketing, and expanding drugmaker partnerships like Eli Lilly for insulin discounts. By early 2017, Blink Health reported about 1 million monthly users with exponential growth, positioning itself to disrupt the opaque prescription drug supply chain amid rising U.S. healthcare deductibles and uninsured populations. The platform bundles users to negotiate better discounts, saving middle-class consumers thousands annually, and aims to onboard all major drug manufacturers. Challenges included a 2016 lawsuit from an ex-employee and later issues like Walgreens exiting its pharmacy network and a 2023 dispute with partner MedImpact. Blink Health continues focusing on price transparency, delivery, and tech-driven affordability in pharmaceuticals. |
Who has invested in BlinkRx?
8 investors have backed BlinkRx across its funding rounds, including 8VC, BoxGroup, LeFrak, SuRo Capital, Burch Creative Capital and The K Fund.
Lead investors include 1789 Capital, SuRo Capital and 8VC.
BlinkRx Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Apr 2016 | ||
| 1 | Lead | Oct 2020 | ||
| 1 | Participant | Oct 2020 | ||
| 1 | Participant | Apr 2017 | ||
| 1 | Participant | Oct 2020 | ||
| 1 | Participant | Apr 2016 | ||
This data is available for Pro users. Sign up to see all 8 BlinkRx investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialBlinkRx Competitors
BlinkRx competitors include listed companies like PB Fintech, Ziff Davis and Zip, and private ones like Firstp2p, Morpho Labs and Avant.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $708M | $58M | $8.5B | 10.1x | ||
| Private | - | - | $2B | - | ||
| Private | - | - | $2B | - | ||
| Private | - | - | $2B | - | ||
| Publicly listed | $1.5B | $335M | $2B | 1.0x | ||
| Publicly listed | $951M | $296M | $2B | 3.6x |
BlinkRx Public Comps
BlinkRx is still privately-owned, but its public comps include Ziff Davis, Zip, LendingClub, Pagaya, Upstart, Wealthfront, Autohome, Moltiply Group, PROG Holdings and Capri Global Capital.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.5B | $335M | 0.9x | 1.0x | 3.8x | 3.3x | |||
| $951M | $296M | 3.8x | 3.6x | 12.2x | 18.3x | |||
| $998M | - | 2.2x | 2.1x | - | - | |||
| $1.3B | $33M | 1.1x | 1.0x | 42.6x | 3.2x | |||
| $1B | $230M | 3.9x | 3.0x | 17.4x | 14.5x | |||
| $365M | ($93M) | 4.3x | 4.2x | (17.0x) | 9.9x | |||
| $962M | $171M | 0.0x | 0.0x | 0.0x | 0.0x | |||
| $787M | $148M | 2.4x | 2.3x | 13.0x | 8.6x | |||
This data is available for Pro users. Sign up to see all BlinkRx competitors and their valuation data. Start Free Trial | ||||||||
Common questions about BlinkRx
| When was BlinkRx founded? | BlinkRx was founded in 2014. |
| Where is BlinkRx headquartered? | BlinkRx is headquartered in United States. |
| Is BlinkRx publicly listed? | No, BlinkRx is a private, VC-backed company. |
| What is BlinkRx's valuation? | BlinkRx was last valued at $2B in its Series D in November 2024. |
| How much funding has BlinkRx raised? | BlinkRx has raised $315M across 4 funding rounds. |
| What was BlinkRx's last funding round? | BlinkRx's last funding round was a $140M Series D in November 2024, led by 1789 Capital. |
| Who are BlinkRx's investors? | BlinkRx's investors include 8VC, SuRo Capital, The K Fund, BoxGroup, Sweetwater Capital Partners, LeFrak, 1789 Capital and Burch Creative Capital. |
| Which companies are comparable to BlinkRx? | Companies comparable to BlinkRx include PB Fintech, Firstp2p, Morpho Labs, Avant, Ziff Davis and Zip. |
See companies similar to BlinkRx
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




